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Mast cells (MCs) contribute to the pathogenesis of
obesity and diabetes. This study demonstrates that
leptin deficiency slants MCs toward anti-inflamma-
tory functions. MCs in the white adipose tissue
(WAT) of lean humans and mice express negligible
leptin. Adoptive transfer of leptin-deficient MCs
expanded ex vivomitigates diet-induced and pre-es-
tablished obesity and diabetes in mice. Mechanistic
studies show that leptin-deficient MCs polarize mac-
rophages from M1 to M2 functions because of
impaired cell signaling and an altered balance be-
tween pro- and anti-inflammatory cytokines, but do
not affect T cell differentiation. Rampant body weight
gain in ob/ob mice, a strain that lacks leptin, associ-
ates with reducedMC content inWAT. In ob/obmice,
genetic depletion of MCs exacerbates obesity and
diabetes, and repopulation of ex vivo expanded ob/
ob MCs ameliorates these diseases.
INTRODUCTION
Obesity and diabetes involve chronic inflammation (Gregor and
Hotamisligil, 2011) mediated by a repertoire of inflammatory
cells, including macrophages, B cells, T cells, neutrophils, eosin-
ophils, and mast cells (MCs) (Weisberg et al., 2003; DeFuria
et al., 2013; Matarese et al., 2012; Talukdar et al., 2012; Wu
et al., 2011; Liu et al., 2009). We previously established that acti-
vated MCs operate in diet-induced obesity (DIO) and diabetes in
mice by releasing interferon-g (IFN-g) and interleukin-6 (IL6),
cysteinyl cathepsins, chymase, and tryptase to activate vascular
cells or adipocytes and promote adipose tissue angiogenesis,
liver glycogenesis, and adipocyte differentiation (Liu et al.,
2009). Mice with DIO exhibit increased plasma MC activators
substance P and IgE (Moreno et al., 2014). Human plasma con-Cell Metabcentrations of tryptase, a MC-specific enzyme, increase with ris-
ing body mass index (BMI) (Fenger et al., 2012) and correlate
with body fat mass, glycated hemoglobin, fasting insulin level,
and homeostasis model assessment-estimated insulin resis-
tance (HOMA-IR) index (Ramalho et al., 2012). Although a recent
study using anemic MC-deficient KitW/Wv mice and CpaCre/+
mice that affect more than just MCs (Reber et al., 2012) claimed
a negligible role of MCs in obesity and diabetes (Gutierrez et al.,
2015), MC stabilizer ketotifen reduces BMI, HbA1c, fasting
blood glucose, low-density lipoproteins, and triglyceride, and in-
creases adiponectin and high-density lipoproteins among obese
and diabetic patients (El-Haggar et al., 2015).
Macrophages (F4/80+CD11b+) drive obesity-associated
inflammation and diseases. WAT from obese humans and ani-
mals (Weisberg et al., 2003) exhibit increased macrophage
numbers. Selective depletion of macrophages or abrogation of
the CCR2-MCP-1 (monocyte chemotactic protein-1) cascade
that mediates macrophage recruitment reduces WAT inflamma-
tion and improves insulin sensitivity in DIO mice (Patsouris et al.,
2008; Weisberg et al., 2006). Macrophage polarization also
influences obesity. M2 macrophages, also called alternatively
activated macrophages, express arginase (Arg)-1 and CD206
(mannose receptor) and associate with metabolic homeostasis
in lean WAT (Chawla et al., 2011). M2 cells also produce IL10,
an anti-inflammatory cytokine, in response to Th2 cytokines
IL4 and IL13 (Lumeng et al., 2007), and contribute to the mainte-
nance of insulin sensitivity (Liao et al., 2011). IFN-g drives the po-
larization of M1 macrophages, also called classically activated
macrophages, and promotes M1 cell expression of proinflam-
matory cytokines TNF-a, IL6, IL1b, IL12, and MCP-1 (Mathis,
2013). M1 cells express CD11c and high levels of iNOS,
TNF-a, and IL6, which impede insulin signaling in adipocytes
and therefore promote insulin resistance and obesity-associated
inflammation (Weisberg et al., 2003, 2006; Lumeng et al., 2007).
Past observations of obese WAT revealed a skewed M1/M2
polarization that enhances WAT inflammation (Shaul et al.,
2010). This observation engendered the hypothesis that M1 cells
predominate in WAT during obesity. The stimulation of M2 cells
using omega-3 fatty acids or thiazolidinediones during obesityolism 22, 1045–1058, December 1, 2015 ª2015 Elsevier Inc. 1045
Figure 1. Leptin Expression in Lean and Obese Humans and Mice
(A) Leptin immunofluorescent staining of WAT from lean and obese humans.
(B) Leptin and MC tryptase immunofluorescent double staining of WAT from lean and obese humans.
(C) Leptin immunofluorescent staining of WAT from lean and DIO mice.
(D) Leptin and CD117 immunofluorescent double staining of WAT from lean and DIO mice.
(E) RT-PCR (left) and immunoblot (right) detected leptin expression in MCs isolated from lean and DIO WAT.
(F) Leptin and CD117 immunofluorescent double staining of total bone marrow cell preparation from lean and DIO mice.
(G) RT-PCR detected adiponectin expression in WAT, purified MCs from WAT, and BMMCs, all from lean mice.
(legend continued on next page)
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improves metabolic function and mutes adipose tissue inflam-
mation (Patsouris et al., 2008; Oh et al., 2010). Several conditions
regulate macrophage polarization, including exposure to free
fatty acids, fetuin-A, Kru¨ppel-like factor-4, or cold temperatures
(Chawla et al., 2011; Liao et al., 2011; Nguyen et al., 2011; Pal
et al., 2012). The most abundant immune cells in WAT after mac-
rophages are CD3+ T cells. Compared to lean mice, WAT from
obese mice (Morris et al., 2013; Winer et al., 2009) contain
increased numbers of CD4+ and CD8+ T cells. Moreover, WAT
from obese mice harbors fewer regulatory T cells (Tregs) that
maintain self-tolerance and dampen Th1 and Th17 responses.
The peptide hormone and satiety factor leptin regulates body
weight by suppressing appetite and stimulating energy expendi-
ture. Its serum concentration and gene expression in adipocytes
correlate with body fat storage and remain elevated in obese
individuals. Leptin modulates a wide range of immune and in-
flammatory processes. Inflammatory stimuli (e.g., TNF-a, IL1,
or lipopolysaccharide [LPS]) stimulate leptin expression in adi-
pose tissues (Grunfeld et al., 1996), and leptin in turn promotes
proliferation, survival, migration/chemotaxis, cytokine/prote-
ase/adhesion molecule expression, and oxidative stress of
nearly all tested cell types. Leptin-responsive cells include those
implicated in cardiometabolic metabolic diseases, such as den-
dritic cells, basophils, endothelial cells, and neutrophils (Suzu-
kawa et al., 2011; Ottonello et al., 2004; Mattioli et al., 2009;
Kato et al., 2011). Leptin also activates monocyte proliferation
and cytokine/chemokine expression, oxidative burst (Tsiotra
et al., 2013; Santos-Alvarez et al., 1999), macrophage phagocy-
tosis, cytokine expression, oxidative stress, and chemotaxis
(Gruen et al., 2007). It also promotes Th1 cell cytokine and adhe-
sion molecule expression and proliferation/survival and con-
strains Treg expansion (Mattioli et al., 2005; Lord et al., 1998;
Martı´n-Romero et al., 2000; Ferna´ndez-Riejos et al., 2008; De
Rosa et al., 2007). Leptin drives naive T cells toward Th1 polari-
zation by stimulating the synthesis of IL2, IL12, and IFN-g and in-
hibiting T cell expression of IL10 and IL4 (Mattioli et al., 2005;
Martı´n-Romero et al., 2000; Batra et al., 2010). In obese humans,
plasma leptin levels correlate with inflammatory biomarkers
(C-reactive protein, serum amyloid A, and IL6) (Meyers et al.,
2008). Compared to controls, patients with metabolic syndrome
have 6-fold higher plasma leptin concentrations that correlate
positively withWATMC numbers (Chaldakov et al., 2001). Leptin
deficiency associates with reduced circulating CD4+ T cell
counts and impaired T cell proliferation and cytokine release
(Farooqi et al., 2002).
This study revealed that WAT from lean humans and mice ex-
pressed higher leptin levels than those from obese subjects, but
MCs inWAT from lean subjects expressed negligible leptin. Lep-
tin deficiency of MCs favored acquisition of an anti-inflammatory
slant that polarized macrophages toward M2 functions without
affecting T cell differentiation. Leptin-deficient mice lacking(H) RT-PCR (left) and immunoblot (right) detected leptin expression in BMMCs p
loading.
(I) Leptin and Mac-2 or CD3 immunofluorescent double staining of WAT from lea
(J) Leptin and CD117 immunofluorescent double staining of liver from lean and D
(K and L) RT-PCR (K) and culture medium ELISA (L) detected leptin expression in
WAT samples, n = 12 per group for mouseWAT and liver samples, n = 3–6 for RT-
shown to the right. Scale bar, 50 mm.
Cell MetabMCs showed augmented body weight gain and glucose intoler-
ance. Restoration of leptin-deficient MCs to genetic obese and
DIO mice or mice with pre-established diseases limited the pro-
gression of these diseases.
RESULTS
MCs in Lean Adipose Tissues Show Reduced Leptin
Expression
Obese patients (Chaldakov et al., 2001) and DIO mice (El-Ha-
schimi et al., 2000) exhibit increased plasma leptin levels. Yet
immunostaining of WAT paraffin sections from obese and lean
humans demonstrated that WAT from lean subjects (n = 17) con-
tained twice as much leptin as in WAT from obese patients (n =
17) (Figure 1A). In contrast, WAT MC in lean subjects contained
little or no leptin, while those from obese patients had 5-fold
higher leptin (Figure 1B). We revealed a similar pattern of leptin
expression in WAT from DIO C57BL/6 mice. Leptin levels in
WAT from lean mice were about 3-fold higher than those from
DIO mice (Figure 1C), but leptin expression in MCs from lean
WAT was also 5-fold lower than in MCs from DIO WAT (Fig-
ure 1D). WAT sections from leptin-deficient ob/ob mice showed
no staining, affirming the specificity of the leptin antibody (Fig-
ure 1C). To verify these observations, we used cell sorter-purified
CD117+FcεR1a+ MCs in WAT from lean and DIO mice. Although
leptin mRNA levels were comparable between MCs from lean
and DIO mice (Figure 1E, left), immunoblot demonstrated leptin
expression in MCs isolated from DIO WAT, but negligibly in
MCs isolated from lean WAT (Figure 1E, right). Bone marrow
contains mature MCs (Stevens and Rosenthal, 2001). Immuno-
fluorescent double staining also detected 3-fold higher leptin
expression in MCs from bone marrow preparation from DIO
mice than from lean mice (Figure 1F). RT-PCR detected adipo-
nectin expression in WAT from WT lean mice (positive control),
but not in cell sorter-purified MCs from lean WAT or BMMCs
(negative control) (Figure 1G), affirming the purity of isolated
WATMCs. Both RT-PCR and immunoblot analysis also revealed
much higher leptin expression in BMMCs from DIO mice than in
those from leanmice (Figures 1H). To test whether other immune
cells in lean WAT also show reduced leptin expression, we per-
formed immunofluorescent double staining for leptin and Mac-2
or CD3. As expected, DIO WAT contained many more Mac-2+
macrophages and CD3+ T cells than lean WAT, but we found
comparable leptin expression in macrophages and T cells from
lean and DIO WAT (Figure 1I). The MCs from various organs in
DIO mice did not all express leptin. Immunofluorescent staining
detected negligible leptin expression in MCs from livers from
either lean or DIO mice (Figure 1J). Increased insulin and inflam-
matory cytokines in DIO mice may explain higher leptin expres-
sion in DIO MCs than in lean MCs. We tested this hypothesis by
stimulating BMMCs with insulin, IL6, and TNF-a. Although onlyrepared from lean and DIO mice. GAPDH in (E) and (H) ensured equal protein
n and DIO mice.
IO mice.
WT BMMCs with different treatments as indicated. N = 17 per group for human
PCR, and n = 6 for leptin ELISA. Representative data for (A)–(D), (F), and (H) are
olism 22, 1045–1058, December 1, 2015 ª2015 Elsevier Inc. 1047
Figure 2. Obesity and Diabetes in WT and
MC-Deficient KitW-sh/W-sh Mice and Those
Receiving BMMCs from WT and ob/obMice
(A) Body weight gain, glucose tolerance, insulin
tolerance.
(B) RT-PCR determined WAT expression of CD68,
MCP-1, and CD11c. Immunostaining detected
Mac2+ macrophage in WAT.
(C) Toluidine blue staining detected MC numbers
in WAT from different groups of mice as indicated.
(D) FACS analysis determinedWAT F4/80+CD11c+
M1 and F4/80+CD206+ M2 macrophages.
(E) RT-PCR determined M1 markers (TNF-a and
IL6) and M2 markers (arginase-1 and IL10) in WAT
from different mouse groups as indicated. The
number of mice per group is indicated in the
parenthesis. Representative data for (B) (scale bar,
50 mm) and (C) (scale bar, 50 mm) are shown to
the right.TNF-a increased leptin RNA levels, all three stimuli increased
leptin secretion from BMMCs (Figures 1K and 1L).
Leptin Deficiency Favors Acquisition of an Anti-
Inflammatory by MCs
Low expression of leptin in MCs from lean WAT raised the hy-
potheses that leptin expression affects MC functions that may
affect obesity and associated complications. To test this conjec-
ture, we first produced DIO in wild-type (WT) and MC-deficient
KitW-sh/W-sh mice by feeding mice a Western diet (Liu et al.,
2009). KitW-sh/W-sh mice gained less weight and had better
glucose and insulin tolerance than WT mice (Figures 2A).
KitW-sh/W-sh mice had significantly lower VAT (visceral adipose
tissue) and SAT (subcutaneous adipose tissue) weights, WAT
adipocyte sizes, and serum insulin levels than WT mice (see
Figures S1A–S1C available online). Adoptive transfer of BMMCs
from WT mice, but not those from ob/ob mice that lack leptin,
normalized body weight gain, VAT and SAT weight, adipocyte
size, glucose and insulin tolerance, and serum insulin concentra-
tions in KitW-sh/W-sh -recipient mice (Figures 2A and S1A–S1C).
BMMCs from ob/ob mice also failed to reverse reduced WAT
expression of macrophage CD68 or M1 macrophage CD11c,
chemokine MCP-1, and Mac2+ macrophage accumulation in
WAT in KitW-sh/W-sh recipient mice, unlike those from WT mice,1048 Cell Metabolism 22, 1045–1058, December 1, 2015 ª2015 Elsevier Inc.as determined by RT-PCR and immuno-
staining, respectively (Figure 2B). As we
reported (Liu et al., 2009), leptin deficiency
did not affect donor BMMC homing to
WAT or other organs, such as spleens.
Toluidine blue staining revealed partial
but equal recovery of donor WT and ob/
ob BMMCs in recipient mouse WAT (Fig-
ure 2C), although we also detected simi-
larly reduced numbers of CD3+ T cells
and increased numbers of NIMP+ neutro-
phils inWAT from recipient mice receiving
WT and ob/ob BMMCs (Figure S1D). In
spleens, donor WT and ob/ob BMMCs
also had partial and similar recovery, butMCdeficiency or reconstitution did not affect significantly spleen
contents of macrophages, T cells, or neutrophils (Figure S1E).
FACS analysis demonstrated that MC deficiency reduced WAT
F4/80+CD11c+ M1 macrophages and increased F4/80+CD206+
M2 macrophages. Repopulation of WT BMMCs, but not ob/ob
BMMCs, increased WAT M1 cells and decreased M2 cells in
recipient KitW-sh/W-sh mice (Figure 2D). mRNA profiles of M1
markers TNF-a and IL6, andM2markers Arg-1 and IL10, affirmed
the altered M1 and M2 slant in macrophages in WAT from donor
WT and ob/ob BMMCs (Figure 2E).
In WT DIO mice, administration of additional WT BMMCs
did not affect body weight gain, SAT or VAT weight, adipocyte
size, glucose and insulin tolerances, or serum insulin levels.
However, WT mice that received ob/ob BMMCs showed signif-
icantly reduced obesity (body weight gain, WAT weight, adipo-
cyte size, and serum insulin levels) and improved glucose and
insulin tolerance, and reduced serum insulin levels (Figures 3A
and S2A). Additional WT BMMCs increased WAT expression of
CD68, MCP-1, and CD11c, as determined by RT-PCR, although
the total WAT Mac2+ macrophage content did not change. In
contrast, additional ob/ob BMMCs reduced CD68, MCP-1,
and CD11c expression and macrophage accumulation in WAT
from recipient WT mice (Figures 3B and S2B). WT BMMCs did
not significantly affect WAT M1 or M2 cells, but ob/ob BMMCs
Figure 3. Obesity and Diabetes in WT Mice and Those with Pre-Established Obesity and Diabetes Receiving WT and ob/ob BMMCs
(A) Body weight gain, glucose tolerance, insulin tolerance.
(B) RT-PCR determined WAT expression of CD68, MCP-1, and CD11c.
(C) FACS analysis determined WAT F4/80+CD11c+ M1 and F4/80+CD206+ M2 macrophages and RT-PCR determined WAT TNF-a, IL6, arginase-1, and IL10
expression.
(D) Body weight gain, glucose tolerance, insulin tolerance from mice with pre-established obesity and diabetes followed by MC repopulation.
(E) RT-PCR determined WAT expression of CD68, MCP-1, and CD11c.
(F) FACS analysis determined WAT F4/80+CD11c+ M1 and F4/80+CD206+ M2 macrophages and RT-PCR determined TNF-a, IL6, arginase-1, and IL10 in WAT.
(G) ELISA determinedWAT tissue IFN-g, IL6, IL4, and IL10. (A)–(C) used the samemice, (D)–(G) were from the samemice. Number ofmice per group is indicated in
each parenthesis.
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significantly reduced WAT M1 cells and increased M2 cells
as determined by FACS analysis. WAT from recipients of WT
BMMCs showed significantly increased mRNAs encoding the
M1 markers TNF-a and IL6 and decreased mRNA for the M2
marker IL10, while those receiving ob/ob BMMCs had signifi-
cantly reduced TNF-a and IL6 mRNA and increased Arg-1 and
IL10 mRNA (Figure 3C).
Leptin-deficient BMMCs also attenuated pre-established
diseases. We produced obese and diabetic mice by feeding
WTmice aWestern diet for 6 weeks, then gave these mice either
WT or ob/ob BMMCs, followed by continued consumption of a
Western diet for another 10 weeks. Mice that received ob/ob
BMMCs showed significant reduction in body weight gain, VAT
and SAT weight, and WAT adipocyte sizes; improvement in
glucose and insulin tolerances; and a reduction in serum insulin
levels, whereas donor WT BMMCs did not affect these variables
in recipient mice (Figures 3D and S2C). Again, WT BMMCs
increased WAT expression of CD68, MCP-1, and CD11c, as
determined by RT-PCR. In contrast, ob/ob BMMCs reduced
expression of all of these inflammatory markers in WAT and sup-
pressedWATMac2+ macrophage accumulation (Figures 3E and
S2D). In these mice with pre-established obesity and diabetes,
WT BMMCs did not change WAT M1 or M2 cell contents as
measured by FACS, but significantly increased WAT mRNA of
TNF-a and IL6, and decreased mRNA of IL10. In contrast,
ob/ob BMMCs reduced WAT F4/80+CD11c+ M1 cell content
and WAT expression of TNF-a and IL6, and increased F4/
80+CD206+ M2 macrophages and their expression of Arg-1
and IL10 (Figure 3F). In WT mice, DIO increased WAT proinflam-
matory cytokines IFN-g and IL6, and reduced WAT anti-inflam-
matory IL4 and IL10. Donor WT BMMCs further increased WAT
IFN-g and reduced WAT IL4 and IL10. In contrast, donor ob/ob
BMMCs significantly reduced recipient mice WAT IFN-g and
IL6, and brought up WAT IL4 and IL10 levels to those in WAT
from lean mice (Figure 3G).
Together, in both previously healthy WT mice and those with
pre-established obesity and diabetes, ob/ob BMMCs, but not
WT BMMCs, attenuated the development of dysmetabolism,
corresponding to the less inflammatory profile of MCs lacking
leptin expression.
Leptin-Deficient MCs Polarize Macrophages toward M2
Functions
Reduced leptin expression in MCs from lean human WAT (Fig-
ure 1B) and inMCs from leanmouseWAT and bonemarrow (Fig-
ures 1D–1F) suggests that these MCs exert correspondingly
distinct functions from those in obese WAT. Reduced obesity
and diabetes in MC-deficient KitW-sh/W-sh mice reconstituted
with ob/ob BMMCs (Figure 2), in WT mice receiving ob/ob
BMMC, including those with pre-established obesity and dia-
betes (Figure 3), supported this hypothesis and suggested a shift
in MCs from proinflammatory to anti-inflammatory functions in
the absence of leptin expression. Leptin production by MCs in
WAT may not only influence their own functions, but also those
of neighboring cells in WAT, including macrophages and T cells.
Macrophages are the most abundant inflammatory cells in
WAT (Weisberg et al., 2003). Immunofluorescent staining local-
ized leptin receptor ObR expression to Mac-2+ macrophages
in WAT from WT DIO mice. WAT from ObR-deficient db/db1050 Cell Metabolism 22, 1045–1058, December 1, 2015 ª2015 Elsemice confirmed the anti-mouse ObR antibody specificity. Immu-
noblot analysis also detected ObR expression in bone marrow-
derived macrophages (BMDMs) from WT mice, but not in those
from db/db mice (Figures S3A and S3B). BMMCs from ob/ob
and WT mice may interact differently with macrophages in
WAT or in other peripheral organs. This hypothesis may explain
the observations in Figures 2 and 3: one round of repopulation of
ob/ob BMMCs reduced WAT M1 cell numbers and M1 markers
(TNF-a and IL6), and increased WAT M2 cell numbers and M2
markers (Arg-1 and IL10) in KitW-sh/W-sh mice, WT mice, or WT
mice with pre-established obesity and diabetes. Yet the shift
from M1 to M2 slant in WAT from these recipient mice (Figures
2 and 3) after receiving ob/ob BMMCs might be a consequence
of reduced obesity and diabetes. To test the hypothesis that
ob/ob BMMCs influenced macrophage polarization directly,
we cocultured BMDMs from WT mice with and without M1
macrophage stimulus LPS (Zheng et al., 2013), M2 cell stimulus
IL4 (Ying et al., 2013), or leptin alone. LPS induced macrophage
expression ofM1markers iNOS and TNF-a. Only ob/obBMMCs,
but not WT BMMCs suppressed significantly this activity of LPS.
Addition of leptin did not affect this inhibitory activity of ob/ob
BMMCs (Figure 4A). In contrast, IL4 induced macrophage
expression of M2 markers Arg-1 and IL10. Only ob/ob BMMCs,
but not WT BMMCs further increased the expression of these
anti-inflammatory molecules. Again, addition of leptin did not
affect this activity of ob/ob BMMCs (Figure 4B). At the baseline
without LPS or IL4 treatment, leptin acted as a proinflammatory
molecule to induce BMDM expression of iNOS in the presence
of WT or ob/ob BMMCs (Figure 4A), and suppressed BMDM
expression of Arg-1 and IL10 in presence of WT or ob/ob
BMMCs (Figure 4B). Relative to the expression of M1 and M2
markers in LPS- and IL4-treated macrophages, however, such
baseline levels of these markers were rather moderate. Of
note, BMDMs from leptin receptor-deficient db/db mice acted
identically to WT BMDMs in all treatments (Figures 4A and 4B),
suggesting that the presented role of ob/ob BMMCs in inhibiting
M1molecule expression but enhancing M2molecule expression
was not due to the intrinsic leptin of MCs.
Under the same conditions, however, CD4+ and CD8+ T cells
from WT or ob/ob mice did not affect LPS or IL4-induced iNOS,
TNF-a, Arg-1, and IL10 expression in BMDMs fromWT or db/db
mice (Figures S3A and S3B). Our observations suggest a func-
tion of leptin-deficient MCs in slanting macrophage polarization
from M1 toward M2 phenotypes, and such activity of leptin defi-
ciency may be unique to MCs.
Altered Cytokine Expression in Leptin-Deficient BMMCs
Accounts for Their Anti-Inflammatory Activities
Leptin-deficient BMMCs polarized macrophages toward M2
functions in recipient mice (Figures 2D, 3C, and 3F) and in
cultured BMDMs (Figure 4). Exogenous leptin or absence of lep-
tin receptor expression on macrophages did not affect such ac-
tivity of leptin-deficient BMMCs, suggesting an intrinsic leptin-in-
dependent role of these BMMCs inM2macrophage polarization.
To test this hypothesis, we performed RayBio cytokine and che-
mokine antibody arrays by comparing WT and ob/ob BMMCs in
the presence and absence of leptin. Of the 39 cytokines and che-
mokines represented in this array, eotaxin, IFN-g, IL1a, IL4, IL6,
IL10, IL13, MCP-1, MIP-1a, and MIP-1g in the culture mediumvier Inc.
Figure 4. Leptin-Deficient MCs Polarize Macrophages toward M2
Functions
RT-PCR determined the expression of M1 markers iNOS and TNF-a (A) or M2
markers Arg-1 and IL10 (B) inWT BMDMs treated with and without leptin, LPS,
IL4, WT BMMCs, or ob/ob BMMCs as indicated.from ob/ob BMMCs showed most robust changes from those in
media from WT BMMCs (Figure S4). To verify these observa-
tions, we measured by ELISA selected proteins including proin-
flammatory IFN-g and IL6; anti-inflammatory IL4, IL10, and IL13;
and chemokines MCP-1 and MIP-1a. Although leptin induced
IFN-g and reduced IL6 in WT BMMCs, ob/ob BMMCs produced
significantly reduced amounts of both of these proinflammatory
proteins (Figure 5A). In contrast, ob/ob BMMC culture media
contained significantly higher concentrations of the anti-inflam-
matory cytokines IL4 and IL13 either before or after leptin treat-
ment, although IL10 expression showed no significant differenceCell Metabbetween the two types of cells before and after the treatment
(Figure 5B). Similarly, leptin induced MCP-1 but reduced MIP-
1a in WT BMMCs. Leptin-deficient ob/ob BMMCs released
less of these chemokines before and after leptin treatment (Fig-
ure 5C). To test the hypothesis that such differences in produc-
tion of pro- or anti-inflammatory cytokines accounted for ob/ob
BMMC influences on macrophage polarization, we assessed
BMDM polarization in the presence of LPS or IL4 using WT
and ob/ob BMMCs as experimental controls. In LPS-treated
BMDMs, LPS-induced expression of M1 markers iNOS and
TNF-a was significantly suppressed by BMMCs from ob/ob,
Il6–/– and Ifng–/– mice, but not by those from WT or Il13–/– mice
(Figure 5D), suggesting that reduced IFN-g and IL6 expression
in ob/obBMMCs (Figure 5A) accounted for ob/obBMMCactivity
in reducing macrophage expression of M1 markers iNOS and
TNF-a (Figure 4A). In contrast, IL4-induced macrophage expres-
sion of M2 markers IL10 and Arg-1 was further enhanced by ob/
ob BMMCs, but not by those from WT, Il6–/–, Ifng–/–, and Il13–/–
mice (Figure 5E), suggesting that molecules other than IFN-g,
IL6, and IL13 accounted for ob/ob BMMC activity in enhancing
BMMC expression of Arg-1 and IL10 (Figure 4B).
Altered Laptin Signaling in Leptin-Deficient BMMCs
Accounts for Their Corresponding Cytokine Expression
Differences in production of IL6, IFN-g, IL4, and IL13 between
ob/ob and WT BMMCs (Figures 5A and 5B) may reflect differ-
ences in BMMC degranulation or activation, or differences in
cell signaling that regulate the expression of these cytokines.
IgE is one of the most common MC activators (Xu and Shi,
2012). Both leptin and IgE activated WT BMMCs, as determined
by histamine release. However, leptin-induced histamine release
was fully blunted in ob/ob BMMCs, and we also detected mod-
erate but significant reduction of IgE-induced histamine release
from ob/ob BMMCs (Figure 6A). Such differences between WT
and ob/ob BMMCs in responding to leptin or IgE stimulation
were not due to their differences in expression of leptin receptor
ObR or IgE receptor FcεR1. ObR immunoblot analysis did not
reveal any differences between WT and ob/ob BMMCs, before
or after leptin induction (Figure S5A). FACS analysis also did
not find any differences of FcεR1 expression on IgE-activated
WT and ob/obBMMCs (Figure S5B). Leptin neutralizing antibody
dose-dependently blocked leptin-induced WT BMMC activation
(Figure 6B). The same antibody also dose-dependently inhibited
WT BMMC release of IFN-g and inhibited ob/ob BMMC release
of IL4, but increasedWTBMMC release of IL4 (Figure 6C). These
observations confirmed a direct action of leptin in inducing WT
BMMC IFN-g expression, suppressing WT BMMC IL4 expres-
sion, and enhancing ob/ob BMMC expression of IL4.
Consistent with above-discussed activities of leptin on WT
and ob/ob BMMC cytokine expression, we demonstrated corre-
sponding changes in leptin signaling in ob/ob BMMCs versus
WT BMMCs. Leptin-induced phosphorylations of Syk, p38,
ERK, JNK, AKT, IkBa, and p65 that are responsible for proinflam-
matory cytokine expression were all blunted in ob/ob BMMCs
(Figure 6D, left). In contrast, leptin-induced phosphorylations of
JAK1, STAT1, STAT5, and STAT6 that are responsible for anti-in-
flammatory cytokines were all enhanced in ob/ob BMMCs (Fig-
ure 6D, right). Such activities of ob/ob BMMCs were selective
to leptin. IgE-induced phosphorylations of Syk, p38, ERK, JNK,olism 22, 1045–1058, December 1, 2015 ª2015 Elsevier Inc. 1051
Figure 5. Leptin-Deficient MCs Polarize
M2 Macrophages by Altered Cytokine
Expression
ELISA determined culture medium IFN-g and IL6
(A), IL4, IL10, and IL13 (B), and MCP-1 andMIP-1a
(C) in WT and ob/ob BMMCs treated with and
without leptin. RT-PCR determined the expression
of M1 markers iNOS and TNF-a (D) and M2
markers IL10 and arginase-1 (E) in BMDMs treated
with and without LPS or IL4 and BMMCs from
different mice as indicated.and AKT in ob/ob BMMCs did not differ from those of WT
BMMCs (Figure 6E). Consistent with these cell signaling
changes, synthetic inhibitors for IkBa, ERK, p38, JNK, and
STAT5 all inhibited WT BMMC degranulation (Figure 6F), but
only inhibitors for ERK, p38, and JNK blocked WT BMMC
expression of IFN-g, and only STAT5 inhibitor blocked WT
BMMC IL4 production (Figure 6G). Under baselines without
leptin stimulation, none of the tested cell signaling inhibitors
affectedWT and ob/obBMMC release of IFN-g, IL4, or histamine
(Figure S5C).
Mast Cell Leptin Deficiency Does Not Affect CD4+ T Cell
Differentiation
T cells are the second most abundant inflammatory cells in WAT
(Wu et al., 2007). Leptin deficiency did not affect T cell influences
on macrophage polarization (Figures S3C and S3D), but ob/ob
BMMCs might affect T cell differentiation in addition to macro-
phage polarization. To test this hypothesis, we cultured naive
CD4+ T cells with WT and ob/ob BMMCs using leptin as a pos-
itive control. Leptin increased Th1 differentiation (Mattioli et al.,
2005; Lord et al., 1998; Martı´n-Romero et al., 2000; Ferna´n-1052 Cell Metabolism 22, 1045–1058, December 1, 2015 ª2015 Elsevier Inc.dez-Riejos et al., 2008; De Rosa et al.,
2007) and reduced Th2 differentiation,
but neither WT nor ob/ob BMMCs
affected CD4+ T cell differentiation (Fig-
ure S5D), excluding a direct role of ob/
ob BMMCs on CD4+ T cells.
Low Numbers of MCs in ob/obMice
Contribute to Obesity and Diabetes
in These Mice
We previously demonstrated higher
numbers of MCs in WAT from DIO mice
than those in WAT from lean mice (Liu
et al., 2009), whereas MCs in WAT,
mesenteric and perinephric fat, skeletal
muscle, and the liver, spleen, and thymus
from ob/ob mice resembled those in lean
mice (Altintas et al., 2012), suggestingMC
deficiency in ob/ob mice. Using toluidine
blue staining, we detected higher
numbers of MCs in WAT from ob/ob
mice than those in WAT from lean mice,
but fewer than half of those in WAT from
DIO mice (Figure 7A). Low numbers
of these anti-inflammatory MCs maycontribute to increased body weight gain in ob/ob mice. To
test this hypothesis, we adoptively transferred 1 3 107 ob/ob
BMMCs or WT BMMCs to 5-week-old recipient ob/ob mice.
Compared to those that received PBS, recipient ob/ob mice
showed no differences in body weight gain (Figure 7B), glucose
and insulin tolerances, and serum insulin levels (Figure 7C) after
receivingWTBMMCs. In contrast, one round of transfer of ob/ob
BMMCs significantly reduced body weight gain, increased
glucose and insulin tolerances, and reduced serum insulin levels
(Figures 7B and 7C), demonstrating the ability of a few more ob/
obMCs to ameliorate obesity and diabetes in ob/obmice. While
adoptive transfer of WT BMMCs increased WAT expression of
CD68, MCP-1, and CD11c, indicating increased WAT inflamma-
tion as expected, one round of administration of donor ob/ob
BMMCs significantly reduced the expression of these inflamma-
tory markers (Figure 7D). Consistent with our hypothesis, adop-
tive transfer of WT BMMCs increased WAT M1 cells as deter-
mined by FACS analysis, enhanced WAT expression of TNF-a
and IL6, and decreased IL10 expression (Figure 7E). In contrast,
adoptive transfer of ob/ob BMMCs significantly reduced WAT
expression of all three inflammatory markers (CD68, MCP-1,
and CD11c), reduced WAT M1 cell numbers, and increased M2
numbers (Figure 7E). These data suggest that MC deficiency af-
fects body weight gain in ob/ob mice. To probe this hypothesis
further, we generated ob/ob KitW-sh/W-sh mice that lack MCs.
Compared with male ob/ob mice that showed low numbers
of MCs in WAT, genetic depletion of MCs in male ob/ob
KitW-sh/W-sh mice significantly increased body weight gain,
decreased glucose and insulin tolerance, increased VAT weight,
and induced splenomegaly, likely because of increased inflam-
mation, enlarged WAT adipocyte size, and increased WAT
macrophage content (Figures S6A–S6E). Female mice yielded
the same results (Figures S6F–S6H).
DISCUSSION
This study revealed a previously untested function of leptin
expression on MCs, originated from our initial observation that
WAT from lean humans and mice expressed abundant leptin,
but that MCs from these WAT were leptin deficient. Leptin defi-
ciency blunted MC expression of proinflammatory cytokines
and associated signaling pathways, but enhanced MC expres-
sion of anti-inflammatory cytokines and associated cell
signaling. We demonstrated that it was the reduced proinflam-
matory cytokines and increased anti-inflammatory cytokines,
but not leptin itself, that converted leptin-deficient MCs into
anti-inflammatory cells that carried unique activity in polarizing
M2 macrophages, which predominate in lean WAT (Chawla
et al., 2011; Lumeng et al., 2007; Liao et al., 2011). These activ-
ities of leptin-deficient MCs may contribute to the improved
obesity and diabetes in DIO mice, genetic obese mice, and
those with pre-established diseases, although additional mech-
anisms may also exist.
Leptin-deficient ob/ob BMMCs affected macrophage polari-
zation not because these cells lack leptin, but rather because
they have altered proinflammatory and anti-inflammatory cyto-
kine expression profile due to the leptin lack. In macrophage
polarization assays, the presence or absence of leptin did not
affect the activity of ob/ob BMMCs in changing the macrophage
expression of iNOS, TNF-a, Arg-1, and IL10 (Figure 4). The ob-
servations that Ifng–/– and Il6–/– BMMCs acted similarly to ob/
ob BMMCs in macrophage polarization (Figures 5D and 5E)
and that ob/ob BMMCs showed muted cell signaling for proin-
flammatory cytokine expressions but enhanced cell signaling
for anti-inflammatory cytokine expression (Figures 6D and 6G)
support this hypothesis. In IL4-treated macrophages, only ob/
ob BMMCs, but not those from Ifng–/–, Il6–/–, and Il13–/– mice,
increased the expression of IL10 and Arg-1 (Figure 5E). There-
fore, MC-derived IFN-g and IL6 may explain reducedM1macro-
phages by ob/obBMMCs. Untestedmediators other than IFN-g,
IL6, and IL13 from ob/ob BMMCs may contribute to enhanced
macrophage IL4 expression and M2 macrophage polarization,
a hypothesis that was not studied in this study.
Increased inflammation in WAT from obese humans and mice
contributed to the elevated leptin expression of MCs in these
tissues. MCs in obese WAT from humans and mice showed
elevated leptin expression. MCs in bone marrow and BMMCs
from DIO mice also expressed more leptin than those from
lean mice. These observations may be explained by increased
inflammation in DIO mice. In WAT from DIO mice, we detectedCell Metabmuch higher levels of proinflammatory IFN-g and IL6 but lower
anti-inflammatory IL4 and IL10 than those in WAT from lean
mice (Figure 3G). High levels of WAT insulin, IL6, and TNF-a
may all stimulate BMMC leptin expression (Figures 1K and 1L),
consistent with prior studies showing that TNF-a stimulates ad-
ipose tissue leptin expression (Grunfeld et al., 1996) and circu-
lates at lower concentrations in lean versus obese subjects
(Kern et al., 2001). It remains to be explained that obese humans
and DIO mice have higher plasma leptin concentrations than do
lean subjects (Meyers et al., 2008; Chaldakov et al., 2001), but
we detected 2- to 3-fold more leptin in WAT from lean humans
and mice than in WAT from obese subjects (Figures 1A and
1C). Leptin may exert different activities depending on the
environment or target cell types. Indeed, we demonstrated that
leptin induced MC expression of proinflammatory IFN-g as we
expected (Mattioli et al., 2005; Lord et al., 1998; Martı´n-Romero
et al., 2000; Ferna´ndez-Riejos et al., 2008; De Rosa et al., 2007),
but reduced MC expression of both proinflammatory IL6 and
anti-inflammatory IL4 (Figures 5A and 5B). Therefore, detailed
activities of leptin on MCs under different conditions merit in
depth investigation.
Leptin deficiency did not affect IgE signaling. Leptin deficiency
in MCs mutated the proinflammatory signaling pathway and
cytokine production with concurrent increase of the anti-inflam-
matory signaling transduction and cytokine expression (Figures
6C, 6D, and 6G). Such activity of leptin-deficient MCs did
not necessarily associate with IgE-induced MC activation.
Compared with that of WT BMMCs, IgE-induced histamine
release in leptin-deficient MCs remained high (Figure 6A), and
IgE signaling in ob/ob BMMCs was unaffected (Figure 6E).
Inflammation in WAT from DIO mice did not affect leptin
expression in macrophages and T cells. Different from MCs,
macrophages and T cells in lean and DIOWAT expressed similar
levels of leptin, suggesting that reduced leptin expression in lean
WAT is MC specific and does not apply to other immune cells. In
CD4+ and CD8+ T cells, leptin enhances Th1 cytokine expression
(IL2 and IFN-g) and reduces Th2 cytokine expression (IL4 and
IL10) (Lord et al., 1998; Martı´n-Romero et al., 2000). In WT
BMMCs, leptin stimulated the signaling pathways that also
enhance proinflammatory cytokine expression but reduced
anti-inflammatory cytokine expression (Figures 6C, 6D, and
6G). At this point, leptin acted similarly on T cells andMCs in con-
trolling Th1 and Th2 cytokine expression. Leptin regulates Th1
immunity by promoting Th1 differentiation and proliferation and
constraining Treg expansion (Mattioli et al., 2005, 2009; De
Rosa et al., 2007), consistent with altered Th1 and Th2 cytokines
(Lord et al., 1998; Martı´n-Romero et al., 2000). However, only ob/
ob BMMCs, but not ob/ob CD4+ T cells or CD8+ T cells, reduced
the expression of BMDM M1 markers iNOS and TNF-a and
increased the expression of BMDM M2 markers Arg-1 and
IL10 (Figures 4, S3C, and S3D). Therefore, leptin deficiency in
T cells may have a different role from that in MCs. Further,
MCs in bone marrow or differentiated from bone marrow from
DIO mice expressed more leptin than those from lean mice,
but liver MCs from lean or DIO mice had hardly detectable leptin
(Figure 1J). Therefore, lower leptin expression in MCs from lean
subjects than those from obese subjects may not apply to
MCs in all organs, a phenomenon that remains to be further
explained.olism 22, 1045–1058, December 1, 2015 ª2015 Elsevier Inc. 1053
Figure 6. Leptin Stimulation of MCs and Pro- and Anti-Inflammatory Signaling and Cytokine Expression
(A–C) (A) ELISAdetermined culturemediumhistamine levels inWTandob/obBMMCs treatedwith orwithout leptin or IgE. ELISAdeterminedmediumhistamine (B)
and IFN-g and IL4 levels (C) inWT and ob/obBMMCs treatedwith andwithout leptin, anti-leptin antibody-treated leptin or control IgG1-treated leptin as indicated.
(legend continued on next page)
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Figure 7. Additional Leptin-Deficient MCs Improve Obesity and Diabetes in ob/ob Mice
(A) Toluidine blue staining of MCs in WAT from lean, ob/ob, and DIO mice. Representative data are shown to the left. Scale bar, 200 mm. Inset scale bar, 50 mm.
(B andC) Bodyweight gain (B) and glucose tolerance, insulin tolerance, and serum insulin levels (C) in ob/obmice received PBS,WTBMMCs, and ob/obBMMCs.
(D) RT-PCR determined WAT expression of CD68, MCP-1, and CD11c.
(E) FACS analysis determined F4/80+CD11c+ M1 and F4/80+CD206+ M2 macrophages and RT-PCR determined M1 markers (TNF-a and IL6) and M2 markers
(arginase-1 and IL10) in WAT from different mouse groups as indicated. Number of mice per group is indicated in the parenthesis.Despite these as-yet-unanswered questions, the present data
provide mechanistic insight into heretofore unsuspected func-
tions of MCs in obesity and diabetes, and point to approaches
to modulate these prevalent diseases. Therefore, MCs may act
differently in obesity and diabetes depending on their expression
of leptin. A recent study, however, argues against this hypothesis
(Gutierrez et al., 2015). Although MC-deficient KitW/Wv mice had
protection from DIO and glucose tolerance, MC-specific deple-
tion by inserting Cre to the MC carboxypeptidase A3 gene in
Cpa3cre/+mice did not affect body weight gain and glucose toler-
ance in either DIO or genetic ob/ob obese mice. In recipient
KitW/Wv mice, adoptive transfer of bone marrow cells from
Cpa3cre/+ and Cpa3+/+ mice reversed equally reduced body
weight and improved glucose tolerance. In WT mice on a
C57BL/6 background, MC stabilization with disodium cromogly-
cate (DSCG) also did not affect bodyweight gain (Gutierrez et al.,
2015). Yet this study may not exclude a role of MCs in obesity
and diabetes. The Cre insertion to the carboxypeptidase A3
gene in Cpa3Cre/+ mice possibly depleted other cells in addition(D) Immunoblot of proinflammatory (left) and anti-inflammatory (right) signalin
leptin.
(E–G) (E) Immunoblot of proinflammatory signaling molecules in BMMCs fromWT
histamine (F) and IFN-g and IL4 (G) in WT and ob/ob BMMCs treated with or wit
Cell Metabto MCs that express the carboxypeptidase A3 gene, including
basophils (Voehringer et al., 2004), some T cell progenitors and
thymic T cells (Feyerabend et al., 2009; Taghon et al., 2007),
and some hematopoietic progenitor cells (Franco et al., 2010).
For example, obesity inversely correlates with the production
of thymic T cells (Yoshida et al., 2014). Depletion of thymic
T cells in Cpa3Cre/+ mice will likely enhance obesity. Although
anemic KitW/W-v mice (Reber et al., 2012) also showed reduced
obesity and glucose tolerance (Gutierrez et al., 2015), these
mice also have reduced numbers of neutrophils by 50%–80%
(Chervenick and Boggs, 1969) and basophils (Lantz et al.,
1998), besides a dearth of MCs. Reduction of these cells may
all contribute to the reduced obesity and diabetes in KitW/W-v
mice. For example, neutrophils can play an important role in
obesity and diabetes (Talukdar et al., 2012). Despite this fact,
donor bonemarrow cells fromCpa3+/+ andCpa3Cre/+micemight
correct MC deficiency in KitW/W-v mice. This bone marrow may
concurrently correct the neutrophil reduction in these mice.
Therefore, donor bone marrow from both Cpa3+/+ and Cpa3Cre/+g molecules in BMMCs from WT and ob/ob mice treated with or without
and ob/obmice treated with or without IgE. ELISA determined culture medium
hout leptin, different signaling molecule inhibitors, or vehicle DMSO.
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mice will likely increase obesity, if neutrophils remain essential in
KitW/W-v mice. In contrast, KitW-sh/W-sh mice may have increased
numbers of neutrophils and basophils (Grimbaldeston et al.,
2005), and reduced obesity and diabetes can be fully reversed
by WT BMMCs, but not those lacking MC inflammatory cyto-
kines, excluding the possible role of cells other than MCs (Liu
et al., 2009). Indeed, a recent randomized controlled study
among obese patients with type 2 diabetes showed that MC
inhibition with ketotifen reduced BMI, HbA1c, fasting blood
glucose, blood total cholesterol, and low-density lipoprotein
and triglycerides, but increased blood high-density lipoprotein
and adiponectin (El-Haggar et al., 2015). These clinical data
support a role of MCs in these metabolic diseases, although
confirmation of these preliminary results requires more compre-
hensive clinical studies.EXPERIMENTAL PROCEDURES
Mice
WT (C57BL/6), Il6–/– (C57BL/6, N11), Ifng/ (C57BL/6, N10), ob/ob (C57BL/6,
N10), and db/db (C57BL/6, N22) mice were obtained from the Jackson Labo-
ratories (Bar Harbor, ME). MC-deficient KitW-sh/W-sh (C57BL/6, N > 15) and
Il13/ (C57BL/6, N11) mice have been described previously (Liu et al.,
2009; Stanya et al., 2013). BMMCs were prepared by differentiating bone
marrow cells in IL3 and stem cell factor as described previously (Liu et al.,
2009). BMMC adoptive transfer was performed using 5- or 12-week-old
male KitW-sh/W-sh, WT, or ob/ob mice by tail-vein injection (1 3 107 cells per
mouse). Two weeks postreconstitution, mice started consuming a Western
diet (22.6% protein, 45.2% carbohydrate, 20.1% fat, and 1.25% cholesterol;
Research Diets, New Brunswick, NJ) for 10–16 weeks. Body weight wasmoni-
tored weekly. By the end of each course of Western diet consumption, we per-
formed glucose tolerance and insulin tolerance assays as described (Liu et al.,
2009). Mice were euthanized, blood samples were collected after intracardiac
puncture on heparinized syringes, and subcutaneous adipose tissue
(SAT), visceral adipose tissue (VAT), spleen, kidney, and liver were removed,
weighed, and used for subsequent gene expression studies and histological
and fluorescence-activated cell sorting (FACS) analyses. Mouse fasting
plasma insulin wasmeasured in prefastedmice (16 hr) using the Ultra Sensitive
Insulin ELISA kit (Crystal Chem, Downers Grove, IL). Plasma leptin levels were
measured using Bio-Plex Pros Assays (Bio-Rad, Hercules, CA). Mice were
bred and maintained according to the Guide for the Care and Use of Labora-
tory Animals published by the National Institutes of Health. Harvard Medical
School Standing Committee on Animals approved all animal protocols.
BMMC Cell Signaling
BMMCs fromWT and ob/obmice were stimulated with leptin (50 ng/ml) or IgE
(50 mg/ml) for 30 min, followed by immunoblot analysis to detect p-Syk (1:500,
Abcam), p-JAK2 (1:500), p-STAT3 (1:500), p-STAT5 (1:500), p-STAT6 (1:500),
p-AKT (1:500), p-ERK (1:500), p-JNK (1:500), p-IkBa (1:500), p-p38 (1:500),
p-p65 (1:500), each nonphosphorylated protein (1:500), and GAPDH (1:2,000),
all of which were purchased from Cell Signaling Technology (Danvers, MA).
BMMCs fromWT and ob/obmicewere also used to detect histamine, IFN-g,
and IL4 productions with or without cell signaling inhibitors, including JAK
inhibitor AG490 (10 mM), IkB inhibitor BAY11-7082 (1 mM), PI3K inhibitor
LY294002 (5 mM), ERK inhibitor PD98059 (10 mM), p38 inhibitor SB203580
(7.5 mM), JNK inhibitor SP600125 (3 mM), and STAT5 inhibitor CAS285986-
31-4 (1 mM). BMMCs (106/well) were pretreated with these inhibitors for 1 hr,
followed by incubation with or without recombinant mouse leptin (50 ng/ml)
for another 24 hr. Cell culture medium were collected for ELISA to determine
histamine (Eagle Biosciences, Inc. Nashua, NH), IFN-g (eBioscience), and
IL4 (eBioscience), according to manufacturers’ instructions.
For in vitro leptin blocking experiments, leptin (50 ng/ml) was preincubated
with or without neutralization antibody (0.1–10 mg/ml) for 15 min and then incu-
bated with BMMCs from WT and ob/ob mice for 48 hr. Cell culture medium
was collected for ELISA to determine histamine, IFN-g, and IL4.1056 Cell Metabolism 22, 1045–1058, December 1, 2015 ª2015 ElseStatistical Analyses
All data from humans, mice, or cell cultures were expressed as means ± SEM.
A nonparametric Mann-Whitney test was used for statistical analysis, followed
by a post hoc Bonferroni correction. p < 0.05 was considered statistically
significant.
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